Mawdsleys and Oncoscience GMbH have launched a Named Patient Supply Program to allow Oncologists in the United Kingdom (UK) and Ireland to obtain access to CIMAher® (Nimotuzumab) on an unlicensed basis for the treatment of various types of cancer.   Nimotuzumab has been approved for marketing in 25 different countries worldwide for a variety of…

Mawdsleys is hosting a webinar to help people in the healthcare sector and pharmaceutical industry develop a deeper understanding of Named Patient Programmes. Participants of the webinar will hear how named patient programmes can be successfully implemented to treat patients who need a medicine that is not locally available to…